References
- Plotkin SA. Vaccines: the fourth Century. Clin. Vaccine Immunol.16(12), 1709–1719 (2009).
- Zinkernagal RM. On natural and artificial vaccinations. Ann. Rev. Immunol.21, 515–546 (2003).
- Look M, Bandyopadhyay A, Blum JS et al. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Deliv. Rev.62(4–5), 378–393 (2010).
- Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.4, 145–160 (2005).
- Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine6(4), 523–529 (2010).
- Nordly P, Agger EM, Andersen P, Nielsen HM, Foged C. Incorporation of the TLR4 agonist monophosphoryl lipid a into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8(+) T-cell responses. In Vivo. Pharm. Res. DOI: 10.1007/s11095-010-0301-9 (2010) (Epub ahead of print).
- Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol.185(10), 5677–5682 (2010).
- Faham A, Altin JG. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J. Immunol.185(3), 1744–1754 (2010).
- Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cells subsets. Immunity33, 464–478 (2010).
- Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials28(35), 5344–5357 (2007).
- Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert. Rev. Vaccines9(9), 1095–1107 (2010).
- Rettig L, Haen SP, Bittermann AG et al. Particle size and activation threshold: a new dimension of danger signalling. Blood115(22), 4533–4541 (2010).